We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A couple of things happened today.
PDSB almost hit $10 on a second day of high volume. Rumour that the FDA is going to fast track our lead trial.
Now worth £11.5M of our £14.5M MCap!
Netscientific have a new website! (first time i've seen it anyway)
and today's tweet.
Our portfolio company @FOxBIOSYSTEMS has been awarded €2.5 million @EUeic grant to accelerate the market introduction of unique Extracellular Vesicle (EV) analysis and isolation application.
Our portfolio company FOx Biosystems has been awarded €2.5 million European Innovation Council and SMEs Executive Agency (EISMEA) grant to accelerate the market introduction of unique Extracellular Vesicle (EV) analysis and isolation application.
Thomas van Elzakker, CEO of FOx Biosystems comments: “This grant is a clear validation of the urgent need for the benefits we offer to the fast-growing EV research market. It recognizes the unique potential value of our technology to obtain high quality and unbiased research data in this field, removing the current bottlenecks scientists are struggling with.''
Assume most peeps have sold up their Xmas pot and coming back next year!
Meanwhile , in addition to yesterday, PDS has reported early data on 3 different P2 trials combining its Versamune with either Keytruda, Chemo or 2 drugs from Merck KGaA in HPV16+ cancers. ALL have stellar results.
Companies do not all turn off for Xmas!!
Really interesting slide in $PDSB new slide deck today. Shows the complete elimination of cancer tumour dna circulation in blood. This will increase progression free survival to great lengths. Very excited to see how this transforms cancer treatment paradigm.
RNS OUT!
https://www.linkedin.com/posts/sagetech-medical_sidsolutions-siddock-circulareconomy-activity-7006920583959465984-pMlc?utm_source=share&utm_medium=member_ios
Seems like a lot is going on at Sagetech.
https://www.linkedin.com/posts/carlos-jaureguizar_in-our-second-year-of-eco-disruptive-im-activity-7006679425362649089-uecq?utm_source=share&utm_medium=member_ios
https://www.linkedin.com/posts/emvcapital_constructiontech-eisinvestment-climatechangeinvestment-activity-7006664588930822144-esc-?utm_source=share&utm_medium=member_ios
Proaxis tweeting about the launch of 'K-Postn' which is the product deal they did with Uni of Geneva.
Assume one of the 7 products they now have for sale from the recent interview.
Very good news, if a bit delayed!
ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
FEBRUARY 21, 2021-POSTED BY DAVID RIBEIRO
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of Geneva and the University Hospital of Geneva, today announce that they have reached agreement on a global licensing agreement. Researchers at the University have developed a highly novel assay for a Cathepsin K-dependent periostin cleavage product, as a biomarker of bone fragility related to disorders such as osteoporosis. The technology is currently the subject of patent applications in Europe and the US. As a result of this agreement, ProAxsis will complete the technical validation of the assay, and seek to commercialise the assay in key territories before the end of 2021.
Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:
“We believe this assay will allow the rapid non-invasive identification of subjects at high risk of osteoporotic fractures and potentially other metabolic bone diseases. This is an incredibly exciting addition to our product portfolio and fits with our business growth plans; including identifying and in-licensing diagnostic tools which fulfil a high unmet need.”
Professor Serge Ferrari, Head of Bone Diseases at the University of Geneva and one of the inventors of the assay technology, said:
“Fragility fractures are a major clinical and public health issue, yet identification of subjects at high risk of fracture remains challenging. The high specificity of the Cathepsin K digested periostin fragment for bone thus presents itself as an ideal candidate to improve prediction of bone fragility.”
Dr Jennifer Cadby, Licensing Officer at the University of Geneva, added:
“We’re delighted to have signed this agreement with ProAxsis and are excited to combine the expertise of the groups in Geneva and Belfast.”
Any enquiries concerning ProAxsis’ product portfolio can be directed to info@proaxsis.com. For further information on the University of Geneva, please visit www.unige.ch
About ProAxsis
ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.
This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE level
From ProAxsis Twitter: So proud to announce the launch of ‘K-Postn’. A bone-specific periostin assay, (ELISA). K-Postn has the potential to identify and/or monitor people most at risk of osteoporotic fractures and other bone diseases.
For more info please email info@proaxsis.com
#bonehealth
Good interview by Frank (CEO PDSB).
https://tradersnewssource.com/interview-pdsb/
Our holding worth ~ £10m.
This is a dead donkey, i've written off the 3k i put in this some time back on the hype when it was well over a pound :(
You win some loose some :)
Suprised a tad no interest today. Apart from lack of following, I think many holders don’t understand how £ sig the CUA actually could be, esp in a listing/ takeover
Sofant has a bright future. They are working with some key institutions like ESA. IMO, they will be a takeover target in the future.
Very good. Solid steps
Well TQ, the Fosan payment clears up up your funding doubt - they may have even paid another poa given our boards matter of fact reporting - to me the 1m would warrant a separate a RNS.Anyway, just shows Fosan is keen to address the China market without waiting for the official clinic end - meaning they do not need it for China [and know its a success] - and we get net income - no upfront costs and as Fosan has an existing country wide marketing and distribution network within the biggest market - it looks very good and overlooked [inc by myself as I missed this snippet]
Hopefully another 6 months for so before we get some meaningful news.
‘An expert contract lab has been commissioned to carry out troubleshooting and assay optimisation to complete the training set, which will be a significant value inflection point for the company, now expected in the first half of 2023.
· The company is exploring avenues for commercialisation and opportunities, recognising the significant value inflection points and continues to work closely with Fosun Pharma for the successful development and realisation of returns from the business.’
In the interims, it mentioned Glycotest is due to receive the last tranche from Fosun.
‘The bulk of the significant spend has already been deployed and becomes due for reimbursement by Fosun, under the existing agreement. In 2021, Fosun made a further payment on account of $1 million leaving a balance of $3 million of milestone-based funding to Glycotest.’
https://clinicaltrials.gov/ct2/show/NCT03878550
Updated on the 14th
Where did the end of 2023 date come from?
Nice one
Bit poor that you have to access chinese information for significant info on your lead subsidiary
Sorry, that is not from the latest report from Fuson.
Here is the link for the 2022 Semi-Annual Report. It's in Chinese but you can word search then google translate.
https://www.fosunpharma.com/Upload/File/202208/9ce59f110d1b4280825c9071414372f0.pdf
The below was published in the latest Fuson interims/annual update.
'New products such as microbial mass spectrometer (ASTA) have been launched one after another; the product pipeline includes Glycotest HCC Panel (early liver cancer diagnosis Diagnostic and screening programs), molecular POCT respiratory detection and other diagnostic products with high clinical value.'
Maybe, but consider POLX - they are commercial while waiting FDA - Glyco have a lot of positve data - parallel running is a distinct poss.
Pure conjecture - be nice of the BOD were more forthcoming info wise!